Sutro Biopharma (STRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sutro Biopharma (STRO) has a cash flow conversion efficiency ratio of 0.438x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.19 Million) by net assets ($-87.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sutro Biopharma balance sheet independence to measure how much of total assets are equity-financed.
Sutro Biopharma - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sutro Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sutro Biopharma (STRO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Sutro Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sutro Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digital Mediatama Maxima PT
JK:DMMX
|
-0.035x |
|
Xtra-Gold Resources Corp
TO:XTG
|
0.121x |
|
GIIB Holdings Bhd
KLSE:7192
|
-0.621x |
|
LET co. Ltd
KQ:297890
|
-0.023x |
|
Fortune Indonesia Tbk
JK:FORU
|
-0.061x |
|
Ko Ja Cayman Co Ltd
TW:5215
|
0.019x |
|
Advenica AB
ST:ADVE
|
-0.104x |
|
Premier Polyfilm Limited
NSE:PREMIERPOL
|
0.116x |
Annual Cash Flow Conversion Efficiency for Sutro Biopharma (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sutro Biopharma from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Sutro Biopharma market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $44.60 Million | $-191.54 Million | -4.295x | -475.79% |
| 2023-12-31 | $149.65 Million | $-111.62 Million | -0.746x | -4661.44% |
| 2022-12-31 | $217.05 Million | $3.55 Million | 0.016x | +105.06% |
| 2021-12-31 | $252.56 Million | $-81.68 Million | -0.323x | -58.38% |
| 2020-12-31 | $332.05 Million | $-67.80 Million | -0.204x | +69.29% |
| 2019-12-31 | $97.79 Million | $-65.02 Million | -0.665x | -789.62% |
| 2018-12-31 | $131.54 Million | $12.68 Million | 0.096x | -71.65% |
| 2017-12-31 | $-109.00 Million | $-37.07 Million | 0.340x | +135.06% |
| 2016-12-31 | $-90.90 Million | $-13.15 Million | 0.145x | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more